LUX-Lung 6研究引发的EGFR-TKI治疗19 Del和L858R突变晚期非小细胞肺癌疗效探讨被引量：2

Efficacy of EGFR-TKI Treated with 19 Del and L858R Mutation Advanced Non-Small Cell Lung Cancer: LUXLung 6

下载PDF

导出

摘要 1文献来源Wu YL,Zhou CC,Hu CP,et al.Afatinib versus Cisplatin plus Gemcitabine for first-linetreatment of Asian patients with advanced non-smallcell lung cancer harbouring EGFR mutations（LUXLung 6）：An open-label,randomised phase 3 trial[J].Lancet Oncol,2014,15（2）：213-222.2证据水平1b。3背景表皮生长因子受体（epidermal growth factor receptor,EGFR）酪氨酸激酶抑制剂（tyrosine kinase inhibitor,TKI）与化疗相比,能够明显延长EGFR突变晚期非小细胞肺癌（non-small cell lung cancer,NSCLC）患者的生存期,目前已开展许多相关临床试验,

作者赵明芳刘云鹏娄娜娜

机构地区中国医科大学附属第一医院肿瘤内科广东省人民医院肿瘤中心

出处《循证医学》 CSCD 2015年第1期37-41,共5页 The Journal of Evidence-Based Medicine

关键词非小细胞肺癌阿法替尼 EGFR突变 non-small cell lung cancer Afatinib EGFR mutation

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献16

1Sequist LV, Yang JC, Yamamoto N, et al. Phase m study of Afatinib or Cisplatin plus Pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations[J]. J Clin Oncol, 2013,31 (27) : 3327-3334.
2Wu YL, Zhou C, Hu CP, et al. LUX-Lung 6: A randomized, open-label, phase m study of Afatinib (A) versus Gemcitabine/Cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M + ) advanced adenocarcinoma of the lung[J]. J Clin Oncol, 2013, 31(15s) : abstr 8016.
3Yang JCH, Sequist LV, Schuler MH, et al. Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC)harboring common (DeI19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase m studies (LUX-Lung 3 ILL3] and LUX-Lung 6 [LL6] ) comparing Afatinib with chemotherapy (CT)[J]. J Clin Oncol, 2014,32(15s): Abstr 8004.
4Zhang Y, Sheng J, Kang S, et al. Patients with Exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-Line EGFR- TKIs for advanced non-small cell lung cancer: A meta-analysis [J]. PLoS ONE, 2014,9(9) :e107161.
5Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after Gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence[J]. J Clin Onco, 2005,23 (11) :2513-2520.
6Riely GJ, PaoW, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exonl9 and exon 21 mutations treated with Gefitinib or Erlotinib[J]. Clin Cancer Res, 2006,12(3 Pt 1) :839-844.
7Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with Gefitinib or Erlotinib[J]. Clin Cancer Res, 2006, 12(13) :3908-3914.
8Yoshioka H, Mitsudomi T, Morita S, et al. Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing Gefitinib (G) with Cisplatin plus Docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR)[J]. J Clin Oncol, 2014,32(15s): Abstr 8117.
9Kato T, Seto T, Nishio M, et al. Erlotinib plus Bevacizumab (EB) versus Erlotinib alone (E) as first-line treatment for advanced EGFR mutation X positive non-squamous non-small cell lung cancer (NSCLC): An open-label randomized trial[J].2014,32(15s):Abstr 8005.
10Lee VH, Tin VP, Choy TS, et al. Association of Exon 19 and 21 EGFR mutation patterns with treatment outcome after first- line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer[J]. J Thorac Oncol, 2013,8(9) : 1148-1155.